风湿病学生物DMARD 25年。

IF 29.4 1区医学 Q1 RHEUMATOLOGY

Nature Reviews Rheumatology Pub Date : 2023-11-02 DOI:10.1038/s41584-023-01036-x

Marc Feldmann, Ravinder N. Maini, Enrique R. Soriano, Vibeke Strand, Tsutomu Takeuchi

引用次数: 0

摘要

2023 年是风湿病学领域首个生物制剂药物获得批准的第 25 个年头。在本视点中，五位风湿病学研究人员讨论了生物制剂疗法如何改变了临床实践，反思了他们自身的经验、过去和当前面临的挑战以及生物制剂药物的未来。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

25 years of biologic DMARDs in rheumatology

查看原文本刊更多论文

25 years of biologic DMARDs in rheumatology

2023 marks 25 years since the approval of the first biologic drug in rheumatology. In this Viewpoint, five rheumatology researchers discuss how biologic therapy has transformed clinical practice, reflecting on their own experience, past and current challenges and what the future might hold for biologic drugs.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Reviews Rheumatology 医学-风湿病学

CiteScore

29.90

自引率

0.90%

发文量

137

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Rheumatology is part of the Nature Reviews portfolio of journals. The journal scope covers the entire spectrum of rheumatology research. We ensure that our articles are accessible to the widest possible audience.